Overview

The AP-GELP Study: A Clinical Trial on the Effects of Apremilast in Female Genital Erosive Lichen Planus

Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
Genital erosive lichen planus (GELP) is a chronic inflammatory disease causing painful genital sores and scarring in women. Treatment options are limited and often unsatisfactory. This trial will study the effects of treatment with apremilast and quality of life and sexual function in women with GELP.
Phase:
Phase 2
Details
Lead Sponsor:
Oslo University Hospital
Collaborators:
Amgen
Celgene Corporation
Treatments:
Apremilast
Thalidomide